Darvoni60 mg+400 mg

Darvoni is a combination direct-acting antiviral (DAA) regimen used in the treatment of chronic hepatitis C virus (HCV) infection in adults. Its use should always be guided by a physician (hepatologist or infectious disease specialist) after confirming HCV genotype and assessing liver disease/cirrhosis status.

• Established/guideline-supported use: Treatment of chronic HCV genotype 1, 2, 3, or 4 infection, with or without compensated cirrhosis, as part of a complete antiviral treatment course. Darvoni is formally FDA-approved for HCV genotype 3 infection, and is additionally recommended by WHO and other international treatment guidelines for other genotypes, particularly in settings where genotype-specific alternative regimens are not accessible.
• Combination-dependent use: In select patients (for example, genotype 3 with compensated cirrhosis, or certain treatment-experienced patients), Darvoni is used together with ribavirin to improve treatment response; this addition and the treatment duration depend on genotype, cirrhosis status, and prior treatment history.
• Off-label/expanded use: Darvoni is used off-label in some HCV/HIV co-infected patients and in certain post-liver-transplant HCV recurrence settings, under specialist supervision.

Darvoni is not effective against other types of viral hepatitis (e.g., hepatitis A or B) and does not eliminate the risk of transmitting HCV to others.

Each film-coated tablet/combination pack of Daclatasvir + Sofosbuvir typically provides:

• Daclatasvir (as dihydrochloride) - commonly 60 mg
• Sofosbuvir - commonly 400 mg

Daclatasvir + Sofosbuvir may be supplied either as a fixed-dose combination tablet or as co-packaged individual tablets of daclatasvir and sofosbuvir, taken together once daily. Strength and pack presentation can vary by manufacturer; always check the product label/pack insert dispensed.

Darvoni is a fixed-dose/co-packaged combination of two direct-acting antiviral agents used together to treat chronic hepatitis C virus infection. Daclatasvir is an NS5A replication complex inhibitor, and sofosbuvir is a nucleotide analog NS5B polymerase inhibitor; combining agents that act at two different steps of the HCV replication cycle increases antiviral potency and reduces the likelihood of resistance compared with either agent used alone.

Darvoni is administered orally, once daily, and is typically given for 12 weeks, though duration and the need for additional ribavirin depend on the HCV genotype, presence of cirrhosis, and treatment history. It has substantially changed HCV treatment by offering high cure rates (sustained virologic response) with a relatively short, interferon-free, generally well-tolerated oral regimen.

Darvoni belongs to the therapeutic class of direct-acting antivirals (DAAs) for chronic hepatitis C virus infection. It combines an NS5A inhibitor (daclatasvir) with an NS5B nucleotide polymerase inhibitor (sofosbuvir).

Daclatasvir + Sofosbuvir combines two antiviral agents with complementary, non-overlapping mechanisms of action against HCV:

• Daclatasvir is an inhibitor of the HCV NS5A protein, a non-enzymatic protein essential for viral RNA replication and assembly of new virions. By binding NS5A, daclatasvir blocks both viral RNA replication and virion assembly.
• Sofosbuvir is a nucleotide analog prodrug that is metabolized intracellularly to its active triphosphate form (GS-461203). This active metabolite is incorporated by the HCV NS5B RNA-dependent RNA polymerase into the growing viral RNA chain, acting as a chain terminator and halting HCV replication.

Pharmacokinetics (overview): Daclatasvir is metabolized mainly via CYP3A4 and is a substrate of P-glycoprotein, with a plasma half-life of approximately 12-15 hours, allowing once-daily dosing; it is primarily eliminated via bile/feces. Sofosbuvir is rapidly converted to its active metabolite intracellularly, with the predominant circulating (inactive) metabolite GS-331007 eliminated mainly by the kidneys. Because sofosbuvir clearance depends on renal function, dosing in patients with significant renal impairment requires caution (see Use in Special Populations).

Darvoni is taken orally, once daily, at approximately the same time each day, with or without food. Tablets should be swallowed whole with water and should not be crushed, split, or chewed unless a physician/pharmacist specifically advises otherwise. It is important to complete the full prescribed course exactly as directed, even if symptoms improve, to maximize the chance of viral cure and reduce the risk of antiviral resistance.

Darvoni has clinically significant drug interactions, mainly related to effects on the CYP3A4 enzyme and P-glycoprotein transporter (affecting daclatasvir) and effects on intestinal P-glycoprotein/BCRP (affecting sofosbuvir absorption):

• Strong CYP3A4/P-glycoprotein inducers (e.g., rifampin, certain anticonvulsants such as phenytoin or carbamazepine, St. John's Wort): significantly reduce daclatasvir and/or sofosbuvir plasma concentrations, risking loss of antiviral efficacy and treatment failure. Concurrent use is contraindicated (see Contraindications).
• Amiodarone: Concurrent use of amiodarone with sofosbuvir-containing regimens, including Darvoni, has caused serious, symptomatic bradycardia and reported fatal cases, particularly when combined with another DAA and/or beta-blockers. This combination is contraindicated unless no alternative exists, in which case it should only be used with intensive in-patient cardiac monitoring (see Contraindications and Precautions).
• Strong CYP3A4 inhibitors (e.g., ritonavir-boosted HIV protease inhibitors): can increase daclatasvir exposure, requiring dose reduction of the daclatasvir component under physician guidance.
• Other antiretrovirals/HIV medicines: Some antiretroviral regimens require dose adjustment of daclatasvir or careful monitoring when co-administered with Darvoni; HIV-HCV co-infected patients should be managed by a specialist.
• Acid-reducing agents (antacids, H2-blockers, proton pump inhibitors): May reduce sofosbuvir absorption if taken at high doses simultaneously; spacing of doses or physician guidance is advised.

Most patients tolerate Darvoni well. Reported adverse effects include:

• Common: Fatigue, headache, nausea, diarrhea, insomnia, arthralgia (joint pain), and irritability.
• Less common: Rash, pruritus (itching), dizziness, decreased appetite, myalgia (muscle pain).
• When combined with ribavirin: Additional adverse effects related to ribavirin, most notably anemia (a drop in hemoglobin), can occur and should be monitored for.
• Serious (uncommon but important): Symptomatic bradycardia when co-administered with amiodarone (see Contraindications), and reactivation of hepatitis B virus in HBV/HCV co-infected patients (see Precautions and Warnings).

Patients should seek prompt medical attention for severe fatigue, fainting, very slow heartbeat, signs of liver problems (yellowing of skin/eyes, dark urine, severe abdominal pain), or any severe or persistent adverse reaction while on Darvoni.

Pregnancy: Data on the use of Darvoni in pregnant women are limited. Darvoni should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; treatment decisions should always be made in consultation with a physician. If Darvoni is used together with ribavirin, pregnancy is an absolute contraindication for that combination due to ribavirin's known teratogenic and embryolethal effects, and effective contraception is required for the patient (and, where relevant, the partner) during and for months after such combined treatment - a physician must guide this decision.

Lactation: It is not known whether daclatasvir or sofosbuvir passes into human breast milk. Because many drugs are excreted in breast milk, a decision should be made, in consultation with a physician, whether to discontinue breastfeeding or to discontinue/withhold Darvoni, taking into account the importance of treatment to the mother.

The following precautions apply when using Darvoni:

• Hepatitis B virus (HBV) reactivation: Cases of HBV reactivation, some fatal, have been reported in patients coinfected with HBV and HCV who were treated with direct-acting antivirals, including Darvoni. All patients should be screened for current or prior HBV infection before starting treatment, and HBV-coinfected patients should be monitored during and after treatment per specialist guidance.
• Bradycardia risk with amiodarone: Serious symptomatic bradycardia has occurred when amiodarone is used with sofosbuvir-containing regimens such as Darvoni (see Contraindications). This combination should be avoided; if no alternative exists, it should only be used with cardiac monitoring in an inpatient setting for the first days of co-administration.
• Renal function: Because the major sofosbuvir metabolite is renally eliminated, caution and specialist input are needed when using Darvoni in patients with significant renal impairment.
• Genotype and cirrhosis confirmation: Before starting, HCV genotype should be confirmed and cirrhosis status (compensated vs decompensated) assessed, as these determine the correct regimen, need for ribavirin, and treatment duration.
• Adherence: The full prescribed course of Darvoni should be completed exactly as directed; missed doses, early discontinuation, or dose sharing can reduce the chance of cure and increase the risk of resistance.
• Specialist care: Darvoni should be prescribed and monitored by, or in consultation with, a physician experienced in HCV management (hepatologist/infectious disease specialist), including baseline and on-treatment liver function and virologic monitoring.
• Hepatic decompensation/liver failure: Rare cases of hepatic decompensation and liver failure have been reported in patients treated with sofosbuvir-containing regimens, mostly in those with pre-existing advanced cirrhosis; such patients need close monitoring.

There is limited clinical experience with overdose of Darvoni. In the event of a suspected overdose, the patient should seek immediate medical attention or contact a poison control center/emergency services. Management is supportive, with monitoring of vital signs and clinical status; there is no specific antidote. Do not attempt to manage a suspected overdose at home without professional medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: No dosage adjustment of Darvoni is generally required in mild-to-moderate renal impairment. In patients with severe renal impairment or end-stage renal disease, use requires careful specialist assessment given the renal elimination of the main sofosbuvir metabolite.
• Hepatic impairment: No dose adjustment is required for mild, moderate, or severe hepatic impairment/decompensated cirrhosis, but these patients need close specialist monitoring during Darvoni therapy.
• Elderly patients: No specific dose adjustment is generally required based on age alone; use with the usual caution for age-related comorbidities and concomitant medications.
• HIV co-infection: Patients co-infected with HIV may need dose adjustment of the daclatasvir component or careful review of antiretroviral interactions when using Darvoni; specialist co-management is advised.
• Pediatric patients: See Pediatric Uses.
• Pregnancy and lactation: See Pregnancy and Lactation.

The typical duration of treatment with Darvoni is 12 weeks for most treatment-naive patients without cirrhosis. Treatment may be extended to 24 weeks, and/or combined with ribavirin, in certain patients with compensated cirrhosis, prior treatment experience, or genotype 3 infection, based on specialist assessment and current HCV treatment guidelines. The exact duration must be individualized and should not be shortened or extended without physician advice, as this affects the likelihood of achieving a sustained virologic response (cure).

Daclatasvir + Sofosbuvir belongs to the drug class of direct-acting antivirals (DAAs) used for chronic hepatitis C, specifically combining an NS5A inhibitor (daclatasvir) with an NS5B nucleotide analog polymerase inhibitor (sofosbuvir).

Daclatasvir + Sofosbuvir works through two complementary antiviral mechanisms: daclatasvir inhibits the HCV NS5A protein, blocking viral RNA replication and the assembly of new virus particles, while sofosbuvir is converted intracellularly into an active nucleotide analog that is incorporated into the growing HCV RNA chain by the viral NS5B polymerase, terminating chain elongation and stopping viral replication. Together, these mechanisms produce potent, synergistic suppression of HCV replication and a high rate of sustained virologic response.

The safety and efficacy of Darvoni in pediatric patients have not been well established in most treatment guidelines, and data remain limited compared with adult use. Use of Darvoni in children and adolescents should only be considered under the direct supervision of a pediatric hepatology or infectious disease specialist, following current pediatric HCV treatment guidance, and only when the potential benefit is judged to outweigh the uncertainties of use in this age group. Darvoni is not recommended for use in infants or young children outside of specialist-directed care.